TNF and inflammatory bowel disease: In fact, intensive efforts have been made to treat inflammatory diseases through TNF neutralization, and multiple TNF-blocking agents, such as adalimumab, certolizuman pegol, etanercept, golimumab, and infliximan, are now approved for diseases such as juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, spondylarthritis, inflammatory bowel disease, and uveitis47,48.